title: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
abstract: OBJECTIVE
  To determine the benefits of switching to didanosine compared with continuing zidovudine among patients infected with human immunodeficiency virus (HIV) who have previously used zidovudine and have signs of clinical deterioration.
  
  
  METHODS
  Randomized, double-blind, two-armed, parallel, comparative clinical trial with a blinded, compassionate crossover provision at 12 weeks.
  
  
  METHODS
  Outpatient clinics at 19 tertiary care medical centers.
  
  
  METHODS
  312 patients infected with HIV who had received zidovudine for 6 months or more, had CD4 cell counts of 300/mm3 or less, and had signs of clinical deterioration within 12 weeks before study entry.
  
  
  METHODS
  Peroral didanosine tablets (600 mg/d adjusted for weight, "high dose") or zidovudine capsules (600 mg/d).
  
  
  METHODS
  Primary study end points were death, a new acquired immunodeficiency syndrome (AIDS)--defining event, or the combination of two new or recurrent HIV-related diagnoses with a 50% decrease in CD4 cells.
  
  
  RESULTS
  Switching to didanosine was associated with fewer end points than continuing zidovudine (relative risk [RR] for zidovudine:didanosine = 1.5; 95% Cl, 1.1 to 2.0). This benefit was consistent across subgroups of patients with either AIDS-related complex or AIDS and was most apparent among those with a CD4 count at entry of 100/mm3 or more (RR = 2.2; Cl, 1.1 to 4.4).
  
  
  CONCLUSIONS
  This study shows a positive treatment effect for switching from zidovudine to didanosine among patients with either AIDS-related complex or AIDS and validates the common practice of using clinical signs or a decrease in the CD4 count as an indication for changing therapy.
authors.affiliation: Holy Cross Hospital, Salt Lake City, Utah.
authors.forename: S L
authors.initials: SL
authors.lastname: Spruance
authors.forename: A T
authors.initials: AT
authors.lastname: Pavia
authors.forename: D
authors.initials: D
authors.lastname: Peterson
authors.forename: A
authors.initials: A
authors.lastname: Berry
authors.forename: R
authors.initials: R
authors.lastname: Pollard
authors.forename: T F
authors.initials: TF
authors.lastname: Patterson
authors.forename: I
authors.initials: I
authors.lastname: Frank
authors.forename: S C
authors.initials: SC
authors.lastname: Remick
authors.forename: M
authors.initials: M
authors.lastname: Thompson
authors.forename: R D
authors.initials: RD
authors.lastname: MacArthur
authors.forename: G E
authors.initials: GE
authors.lastname: Morey
authors.forename: C H
authors.initials: CH
authors.lastname: Ramirez-Ronda
authors.forename: B M
authors.initials: BM
authors.lastname: Bernstein
authors.forename: D E
authors.initials: DE
authors.lastname: Sweet
authors.forename: L
authors.initials: L
authors.lastname: Crane
authors.forename: E A
authors.initials: EA
authors.lastname: Peterson
authors.forename: C T
authors.initials: CT
authors.lastname: Pachucki
authors.forename: S L
authors.initials: SL
authors.lastname: Green
authors.forename: J
authors.initials: J
authors.lastname: Brand
authors.forename: A
authors.initials: A
authors.lastname: Rios
authors.forename: L M
authors.initials: LM
authors.lastname: Dunkle
authors.forename: A
authors.initials: A
authors.lastname: Cross
authors.forename: M J
authors.initials: MJ
authors.lastname: Brown
authors.forename: P
authors.initials: P
authors.lastname: Ingraham
authors.forename: R
authors.initials: R
authors.lastname: Gugliotti
authors.forename: A H
authors.initials: AH
authors.lastname: Schindzielorz
authors.forename: L
authors.initials: L
authors.lastname: Smaldone
mesh_terms: D000386:AIDS-Related Complex / Q000188:drug therapy* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D015215:Zidovudine; D016049:Didanosine